Time-of-day of combined chemoimmunotherapy as a prognostic factor in solid tumors

Time-of-day of combined chemoimmunotherapy as a prognostic factor in solid tumors - PRO-TIME

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038238

Enrollment

1000

Registered

2025-11-05

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Patients with solid tumors who received chemoimmunotherapy at the West German Cancer Center Essen. It is being evaluated whether the time of day of therapy administration is a prognostic fact

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Solid tumor, administration of chemoimmunotherapy

Exclusion criteria

Exclusion criteria: non-metastatic stage

Design outcomes

Primary

Measure	Time frame
OS (Overall Survival) Observation period: 01/2018 – 10/2025	—

Secondary

Measure	Time frame
PFS (Progression Free Survival), ORR (Objective Response Rate), DCR (Disease Control Rate), DoR (Duration of Response), TTF (Time to Treatment Failure)	—

Countries

Germany

Contacts

Public ContactSarah Kröll

Universitätsklinikum Essen

sic@uk-essen.de+49 201/723-6121

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026